Clinical trials: Hookworm Infection
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults
Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator americanus hookworm life cycle that are thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source.
- Trial name
- NCT02126462
- Testing
- Na-APR-1 (M74)/Alhydrogel®, Na-GST-1/Alhydrogel®, Hepatitis B vaccine
- Where
- Gabon
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Trichuris Trichiura; Infection, Hookworm Infections
Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm
The rationale of the study is to provide evidence on the efficacy and safety of Emodepside in adults infected with Trichuris trichiura and hookworm.
- Trial name
- EMODEP_PEMBA (NCT05017194)
- Testing
- Emodepside
- Where
- Tanzania
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- Jennifer Keiser
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults
Hookworms digest hemoglobin from erythrocytes for use as an energy source via a proteolytic cascade that begins with the aspartic protease, APR-1.
- Trial name
- NCT01717950
- Testing
- Na-APR-1 (M74)/Alhydrogel®, Gluco-Pyranosylphospho-Lipid A Aqueous Formulation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Soil-Transmitted Helminthiasis (STH)
Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)
This is a Phase 3, multi-center, prospective, randomized, double-blind, placebo-controlled study to evaluate the effectiveness, safety, and tolerability of ZP5-9676 compared to placebo for the treatment of STH infections.
- Trial name
- NCT06128447
- Testing
- ZP5-9676 600 mg dose
- Where
- Brazil
- Volunteers
- 300 people
- Sponsor
- Zero Point Five Therapeutics